Efficacy and Safety of Cilostazol for the Indication of CSPS

Post Marketing Surveillance of Efficacy and Safety of Cilostazol for the Indication of CSPS

This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.

This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction.

Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.

Inclusion Criteria:

• Patient with an experience of cerebral infarction and having a purpose for prevention of recurrence of cerebral infarction.
• Age: more than 18 years of age

Exclusion Criteria:

• Unqualified patients judged by study investigator(s)